Friday's big stock stories: What’s likely to move the market in the next trading session

The market is anticipating several notable IPOs, including crypto exchange Gemini, while the Renaissance IPO ETF is up 22% year-to-date, driven by strong performers like Tempus AI's 163% gain. In pharmaceuticals, Eli Lilly is down 2% YTD, significantly outperforming Novo Nordisk's nearly 37% decline amidst intense diet drug competition. Conversely, luxury furniture company RH reported a quarterly revenue miss and lowered its full-year sales guidance, citing tariff uncertainty, resulting in an almost 8% after-hours stock drop and a 42% YTD decline.

Analysis

The market is displaying significant divergence, with robust investor appetite for high-growth initial public offerings contrasting sharply with headwinds in specific consumer and pharmaceutical sectors. The IPO market's strength is underscored by the Renaissance IPO ETF (IPO) hitting a new high, up 22% year-to-date, fueled by exceptional performers like Tempus AI (TEM), which has surged 163%. This positive sentiment is further supported by the upcoming listings of companies like Gemini and the 116% six-month gain in crypto-related equity CoinShares (CNSRF). Conversely, luxury retailer RH (RH) signals trouble in the high-end consumer space, missing revenue expectations and lowering its full-year sales growth guidance from 10-13% to 9-11%, citing tariff uncertainty. This resulted in an immediate 8% after-hours stock decline, exacerbating its 42% year-to-date loss. In pharmaceuticals, a clear leader is emerging in the diet drug competition, with Eli Lilly's (LLY) modest 2% YTD dip significantly outperforming Novo Nordisk's (NVO) precipitous 37% YTD plunge.

Key Decisions for Investors

• Investors should exercise caution with RH, as the downward revision in full-year sales guidance and the 42% year-to-date stock decline signal significant fundamental and macroeconomic pressures, particularly from tariff uncertainty.
• The stark performance divergence between Eli Lilly (-2% YTD) and Novo Nordisk (-37% YTD) warrants a re-evaluation of positions in the diet drug space, as the market is clearly favoring Lilly's competitive standing.
• While the IPO market's strength, reflected by the IPO ETF's 22% gain, presents opportunities, the extreme 163% run-up in names like Tempus AI suggests a need to scrutinize valuations and manage volatility for new and recent issues.
• Given the high momentum in crypto-related equities like CoinShares (+116% in six months) and the upcoming Gemini IPO, investors should assess their exposure to the sector's inherent volatility and sensitivity to market shifts.